Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Prime Medicine (PRME) Shares Outstanding (2021 - 2025)

Prime Medicine filings provide 5 years of Shares Outstanding readings, the most recent being $180.5 million for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 37.63% to $180.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $180.5 million, a 37.63% increase, with the full-year FY2025 number at $180.5 million, up 37.63% from a year prior.
  • Shares Outstanding hit $180.5 million in Q4 2025 for Prime Medicine, roughly flat from $180.3 million in the prior quarter.
  • In the past five years, Shares Outstanding ranged from a high of $180.5 million in Q4 2025 to a low of $32.4 million in Q3 2021.
  • Median Shares Outstanding over the past 5 years was $97.4 million (2023), compared with a mean of $98.9 million.
  • Biggest five-year swings in Shares Outstanding: surged 199.9% in 2022 and later grew 0.17% in 2023.
  • Prime Medicine's Shares Outstanding stood at $32.4 million in 2021, then surged by 199.9% to $97.2 million in 2022, then increased by 0.17% to $97.4 million in 2023, then skyrocketed by 34.69% to $131.2 million in 2024, then skyrocketed by 37.63% to $180.5 million in 2025.
  • The last three reported values for Shares Outstanding were $180.5 million (Q4 2025), $180.3 million (Q3 2025), and $134.5 million (Q2 2025) per Business Quant data.